ArticleCancer diagnosis & prognosis
Nivolumab-induced Limbic Encephalitis in Gastric Cancer: A Case Report and Literature Review.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Immune checkpoint inhibitors (ICIs), including nivolumab, have markedly improved gastric cancer (GC) outcomes. However, immune-related adverse events involving the central nervous system are rare and potentially life-threatening. Limbic encephalitis is an exceptionally uncommon manifestation, and its clinical course remains poorly understood. We conducted a literature review of ICI-induced encephalitis specifically in patients with gastrointestinal cancers to clarify its clinical characteristics and management. Case Report: We describe the case of an 83-year-old man with unresectable advanced GC who received multiple lines of chemotherapy, including nivolumab as third-line therapy. After more than 40 cycles of nivolumab treatment, the patient developed progressive cognitive decline. Brain magnetic resonance imaging (MRI) revealed fluid attenuated inversion recovery hyperintensity in the right hippocampus, consistent with limbic encephalitis. Nivolumab was discontinued without corticosteroid administration, leading to gradual cognitive recovery. Follow-up MRI demonstrated resolution of hippocampal abnormalities. Conclusion: This case highlights an exceptionally rare instance of nivolumab-induced limbic encephalitis in a patient with GC. While our patient recovered spontaneously after drug discontinuation without corticosteroids, the key clinical implication is that new-onset cognitive decline in elderly patients receiving ICIs should not be misattributed to dementia progression. Early recognition of neurological immune-related adverse events is essential, as continued ICI therapy in unrecognized cases may result in irreversible or even fatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.